Plant owner in talks with WVU to transfer the closed facility | Your money
CHARLESTON, Va. (AP) – The owner of a closed pharmaceutical plant that recently idled hundreds of workers said Wednesday he had started talks to potentially transfer the complex to the University of West Virginia for d ‘possible other commercial uses.
Viatris Inc. said the drugmaker and WVU are in negotiations for the Morgantown facility.
Viatris announced in December that it would lay off workers at the end of July. Labor and advocacy groups have made a final attempt to keep it open.
The plant was previously operated by generic drug company Mylan, which merged with Upjohn last year to form the new company. Viatris, which has announced it will cut 20% of its workforce globally, is now one of the world’s leading manufacturers of generic drugs.
The plant’s closure has left workers scrambling to find new jobs in a state that often tries to attract new businesses to tackle a stagnant economy once dominated by the coal industry.
Viatris said in a statement that he had not received a viable proposal from the pharmaceutical industry to keep the plant open. Viatris maintains research and development operations in Morgantown.
Executive Chairman Robert J. Coury said that given the location of the site, the possible uses and the employment potential, “we have determined that continuing formal discussions at this time with WVU and its affiliates is the most appropriate. absolute next step to consider. “
Gov. Jim Justice said if negotiations are successful, WVU will work with the state’s Department of Economic Development to find potential businesses to use the facility.
“WVU’s goal is to create jobs in north-central West Virginia. This is a great announcement,” Justice said at a press conference.
The Republican governor has said he also wants the 1,500 former workers at the plant to find jobs.
“These people were so good at their jobs,” he said. “Letting them die on the vine is just not the right thing to do.”
Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.